drugset / Trial / NCT02736500
Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
Phase 1/2
Completed
39 enrolled
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Istituto Europeo di Oncologia · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The aim of this phase I-II study is to evaluate the efficacy and toxicity of PRRT with 177Lu-DOTATATE (Lu-PRRT) associated to metronomic chemotherapy with Capecitabine in patients affected by aggressive FDG-positive gastro-entero-pancreatic NET. Moreover to analyze the effects of the capecitabine metronomic schedule on the level of circulating angiogenetic factors.
Timeline
- Start
- 2015-09-02
- Primary completion
- 2017-04
- Completion
- 2019-10-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-DOTATATE | Peptide | 3700 mbq | — |
| Subject | 177Lu-DOTATATE | Peptide | 5500 mbq | — |